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The association 
between gestational diabetes 
and ASD and ADHD: a systematic 
review and meta‑analysis
Jennifer Rowland1,4 & Claire A. Wilson 2,3,4*
There is growing evidence for a role of maternal diabetes in the pathogenesis of neurodevelopmental 
disorders. However, the specific association between gestational diabetes (GDM), as opposed to 
pre‑gestational diabetes, has been poorly isolated. Thus the aim was to systematically review and 
meta‑analyse literature pertaining to prevalence and risk for two neurodevelopmental disorders: 
autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD), when exposed to 
GDM. PubMed, Cochrane Library, EMBASE, PsycINFO and CINAHL were systematically searched for 
eligible literature, with forward and backward citation tracking. Screening for eligibility, risk of bias 
assessment and data extraction were performed by two independent reviewers. 18 studies measuring 
ASD and 15 measuring ADHD met inclusion criteria. On meta‑analysis there was an increased risk of 
ASD (OR 1.42; 95% CI 1.22, 1.65) but not ADHD (OR 1.01; 95% CI 0.79, 1.28). We discuss potential 
mechanisms for these differing risks. Greater understanding of risk factors, including GDM, for these 
neurodevelopmental disorders and potential mechanisms may help inform strategies aimed at 
prevention of exposure to these adversities during pregnancy.
Gestational diabetes (GDM) is glucose intolerance that begins during pregnancy and has an estimated prevalence 
of between 1.8% and 22.3% in Europe, with higher rates in Africa, North and South America and the Middle 
 East1. It is associated with adverse outcomes for mother and baby, including obstetric complications such as 
emergency Caesarean delivery and longer-term risks of Type 2 Diabetes in the mother and metabolic syndrome 
in  offspring2.
There is also some emerging evidence for a relationship between GDM and adverse neurobehavioural out-
comes in children. Several systematic reviews suggest an association between maternal diabetes and lower IQ 
scores, language impairment and symptoms of attention deficit hyperactivity disorder (ADHD) and autism 
spectrum disorder (ASD). However, many of these reviews group together women experiencing pregestational 
(Type 1 and Type 2) and gestational diabetes so do not investigate the effect of GDM  specifically3–8. While GDM 
and pregestational diabetes share similar pathology of insulin resistance, in GDM this insulin resistance arises 
only during pregnancy, which is itself a state of insulin resistance. Therefore, while there may be some women 
diagnosed with GDM who have undiagnosed pregestational diabetes, the pathology is slightly different between 
the two conditions. There are many potential mechanisms that may underpin such an association between GDM 
and adverse offspring neurobehavioural outcomes. There may be mediating factors of obstetric and neonatal 
adversities such as pre-eclampsia or infants born large for gestational  age9–11. There may also be epigenetic 
 changes12 or oxidative  stress13,14 resulting from a hyperglycaemic in-utero environment.
Thus, the aim of this study was to conduct a systematic review and meta-analysis of the prevalence and risk 
for ADHD and ASD in children of women affected specifically by GDM. Both ADHD and ASD are commonly 
diagnosed neurodevelopmental disorders encompassing a spectrum of neurobehavioural symptoms that are often 
diagnosed from a young age. ADHD has a global prevalence of around 5%15, is characterised by symptoms of inat-
tention and  hyperactivity16 and often has broad and enduring adverse impacts on quality of life and  functioning17. 
ASD describes a range of conditions characterised by some or all of: impaired communication, impaired social 
interaction and repetitive, restricted and stereotyped  behaviour16 and may also result in profound struggles in 
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both personal and professional life. A range of pathophysiological mechanisms have been implicated for these 
neurodevelopmental disorders, including hyperglycaemia during  pregnancy18. Thus, a greater understanding of 
the aetiology of these disorders could help to identify early life risk factors for their development.
Methods
The review followed ‘Meta-analysis of Observational Studies in Epidemiology’ (MOOSE)19 and ‘Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses’ (PRISMA)  guidelines20 and was registered with PROSPERO 
(CRD42019128376).
Search strategy. An electronic literature search was performed in the databases PubMed, Cochrane 
Library, EMBASE, PsycINFO and CINAHL from inception to 04/04/2019, with forward and backward citation 
tracking of eligible papers. Search terms were adapted from previous systematic reviews in the area (see supple-
mentary material). Two separate searches were conducted for ASD and ADHD.
Study selection. Inclusion criteria were: published, peer-reviewed studies with children aged 18 and under, 
whose mothers had clinically diagnosed GDM during pregnancy and who were investigated for symptoms and/
or diagnosis of ASD or ADHD. Report of symptoms of ASD and ADHD by questionnaires or other tests was 
accepted and clinical diagnosis was accepted through self-report, report from medical professionals or medical 
records. Either self-report of GDM, report from medical professionals, or medical records was accepted. Obser-
vational studies and baseline data from intervention studies were included, in any language.
Exclusion criteria were: case studies, editorials, reviews and conference abstracts. Non-human studies were 
also excluded. Studies which were known to include women with established pregestational diabetes were 
excluded, unless it was possible to extract data pertaining specifically to GDM. Studies in which there was some 
doubt surrounding this were included in the review but not included in the meta-analysis.
Two independent reviewers screened titles and abstracts then full texts for eligibility. Results of study selec-
tion are presented in Figs. 1 and 2.
Data extraction and risk of bias assessment. Two independent reviewers extracted data, including 
study characteristics, prevalence and odds ratios (ORs) and any information on mechanisms for the associations. 
Study authors were e-mailed to request raw data if potentially relevant data may be available.
Risk of bias in all included studies was also assessed by two independent reviewers using a pre-piloted modi-
fied Newcastle Ottawa Scale (see supplementary material). Scores for selection bias and measurement bias were 
of particular interest as most of the studies were of observational design. Each question in the tool had a score 
of zero to two (low to high risk of bias). A score of two on any item within the selection and measurement bias 
domains meant that the study was categorised as having a high risk of bias.
Figure 1.  Flow diagram of ASD study selection.
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Data synthesis. Meta-analyses of ORs and prevalence were undertaken separately for ASD and ADHD if 
at least five studies were  available21. In studies providing only prevalence data, ORs were calculated from this 
data (or raw data provided by authors). If there was any doubt as to whether or not pregestational diabetes had 
been excluded from the comparison group without GDM, these studies’ ORs were not included in meta-analysis.
Data were analysed using Stata 15. Metan and metaprop commands were used to produce pooled unadjusted 
ORs and prevalence and 95% confidence intervals (CIs) displayed as forest plots. Insufficient numbers of studies 
adjusted for similar characteristics to enable pooling of adjusted ORs. DerSimonian-Laird random effects meta-
analysis22 was used as there was expected to be substantial heterogeneity between  studies23,24. Heterogeneity was 
assessed using  I2: proportion of total variation in study estimates that is due to  heterogeneity25. It was decided 
a-priori that  I2 > 75% would preclude meta-analysis as this represents considerable  heterogeneity26. Both of the 
prevalence meta-analyses produced  I2 > 75% so prevalence is presented as median with interquartile range (IQR) 
as a standard summary measure of non-parametric data. Sensitivity analyses on effect of risk of bias were con-
ducted when sufficient studies were available. Publication bias was not assessed for the meta-analyses as there 
were insufficient numbers of studies (less than ten)27.
Results
Characteristics of ASD studies. 18 studies measuring ASD were identified; three of these also measured 
ADHD. Table 1 provides a summary of their characteristics and findings. Nine of these studies were from North 
America. Four were from middle income countries; none were from low- income countries (according to World 
Bank classification at June 2019). All studies were observational. Most of the studies used medical records or 
parental report of ASD and GDM; diagnostic criteria for GDM were usually not reported. 11 of the studies were 
assessed as high risk of bias due to lack of information about how GDM or ASD was diagnosed, increasing the 
risk of measurement bias and/or lack of information about selection criteria preventing accurate assessment of 
risk of selection bias.
Pooled odds and prevalence of ASD in those exposed to GDM. Data on prevalence of ASD in those 
exposed to GDM were available for 15 studies; there were three studies which measured ASD and GDM but 
from which prevalence data could not be  extracted28–30 (see Table 1). Heterogeneity on meta-analysis of these 15 
studies was 98%, precluding meta-analysis. Median prevalence was 16.3% (IQR 0.9–48.8%).
Eight of these studies were included in a meta-analysis of ORs. Studies were excluded in the absence of a 
control group or if there was doubt that pregestational diabetes had been excluded from the control group (not 
specifically mentioned in the exclusion criteria and no response to an e-mail to clarify). Pooled unadjusted OR 
was 1.42 (95% CI 1.22, 1.65) with heterogeneity 29% (see Fig. 3).
Figure 2.  Flow diagram of ADHD study selection.
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Characteristics of ADHD studies. 15 studies measuring ADHD were identified. Table 2 provides a summary of 
their characteristics and findings. Compared to those studies measuring ASD, more of these studies were from 
European countries. All studies were observational; ten were prospective cohorts but there were less population-
based cohorts than in the ASD literature so sample sizes were generally smaller. Moreover, measurement of 
symptoms using questionnaires were more frequently used in the ADHD literature (as opposed to diagnoses) 
and this in part led to only two studies being assessed as low to moderate risk of bias.
Author and year Study design Country
Sample size and 
age of children at 
diagnosis
Ascertainment of 
GDM diagnosis ASD measure
Findings
[%, mean (SD), 
OR/HR/RR/β 
(95% CI)]
Risk of bias score 
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Table 1.  Summary of studies measuring ASD. % percentage, SD standard deviation, OR odds ratio, HR hazard 
ratio, RR risk ratio, β β coefficient, CI confidence interval. *Calculated by subtracting data for mothers with 
pregestational diabetes from data for non-GDM mothers.
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Pooled odds and prevalence of ADHD in those exposed to GDM. Data on prevalence of ADHD in those exposed 
to GDM were available for eight studies. Heterogeneity on meta-analysis of prevalence from these eight studies 
was 93.7%, precluding meta-analysis. Median prevalence was 14.4% (IQR 6.7–41.3%).
Studies not included in meta-analysis were those presenting numerical scores on a symptom-based question-
naire, as opposed to numbers scoring above or below a defined threshold, precluding the calculation of prevalence 
or odds (see Table 2). Relatively small numbers of children are included in these studies, with only one study 
including over 100 children exposed to  GDM31. All but one of these studies found no evidence of differences in 
scores between GDM exposed and unexposed children; one study found some evidence for greater concentration 
and inattention symptoms in children of mothers with versus those without  GDM32, which was attenuated on 
adjustment for a range of obstetric, neonatal and sociodemographic confounders (see Table 2)..
Five of the eight studies providing information on prevalence were included in a meta-analysis of ORs; three 
studies were excluded for the same reasons as in the ASD meta-analysis i.e. unable to verify that pregestational 
diabetes had been excluded from the control population. Pooled unadjusted OR was 1.01 (95% CI 0.79, 1.28) 
with heterogeneity 26.2% (see Fig. 4).
Sensitivity analyses. In the meta-analysis of ORs for ASD, it appeared that effect sizes were slightly larger for 
those studies at low to moderate risk of bias. However, removal of the two studies at high risk of bias from the 
meta-analysis resulted in little change. Indeed, the pooled OR was slightly reduced at 1.39 (95% CI 1.19, 1.63). 
There were insufficient numbers of studies to facilitate the same sensitivity analysis for ADHD.
Discussion
Main findings. Pooled OR for risk of ASD following exposure to GDM was 1.42 (95% CI 1.22, 1.65) and 
for ADHD was 1.01 (0.79, 1.28). In general, studies measuring ADHD more often utilised screening tools of 
symptoms in smaller populations than the studies measuring ASD, which more often measured clinical diagno-
ses within larger population-based cohorts. Median prevalence of ASD of 16.3% and ADHD of 14.4% in those 
exposed to GDM is higher than that estimated in the general  population15,33. However, there was substantial 
heterogeneity between studies included in these estimates, also reflected in wide IQRs for these medians and 
indicative of the broad range of study designs, populations and measures of both exposure and outcomes. That 
ORs in these studies when comparing risk in the GDM exposed versus unexposed were only modestly elevated 
also suggests that rates of ASD and/or ADHD were elevated in the study population as a whole, either due to 
selection of at-risk samples or due to systematic measurement of symptoms. Nonetheless, pooled unadjusted OR 
for risk of ASD in those exposed to GDM of 1.42 provides some evidence for a slightly increased risk, not seen 
to the same extent for ADHD (OR 1.01). Two previous meta-analyses investigating only risk for ASD found an 
increased risk; one with a pooled relative risk (RR) of 1.63 had substantially more heterogeneity  (I2 75%)7 and 
the other with RR between 1.48 and 1.72 did not separate pregestational and gestational  diabetes6. In contrast 
to our meta-analysis, in a meta-analysis of risk for ADHD following exposure to GDM across four studies, RR 
Figure 3.  Forest plot showing pooled unadjusted odds ratios for ASD in those exposed to GDM versus those 
not exposed to GDM.
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was 2.0 (95% CI 1.42, 2.81)5. However, as previously discussed, these meta-analyses did not specifically exclude 
pregestational diabetes from their control populations, which may explain the difference in results.
Strengths and limitations. This is the first study to our knowledge that has rigorously reviewed the lit-
erature and meta-analysed prevalence and risk from studies pertaining to both diagnoses and symptoms of ASD 
and ADHD. Using the same review strategy for more than one neurodevelopmental disorder allows a direct 
comparison of risk across a range of disorders. Another unique strength of this review is the exclusion from 
meta-analysis those studies in which pregestational diabetes was not removed from the control population. As 
previously discussed, pregestational and gestational diabetes differ somewhat in their pathology which could 
have implications for the degree of risk for adverse neurobehavioural outcomes and potential mechanistic path-
ways discussed below. However, just as the degree of glucose intolerance may differ between pregestational and 
gestational diabetes, it can also differ between populations with GDM due to widespread variation in diagnostic 
criteria. A significant limitation of the studies included within this review is that most of them do not provide 
information on GDM diagnostic criteria or any other indicators of GDM severity such as use of insulin or medi-
cation. Yet there is now evidence that maternal hyperglycaemia even below that of diagnostic threshold for GDM 
may be associated with adverse obstetric and neonatal  outcomes34. It may be useful for future studies to investi-
gate the impact of severity of maternal hyperglycaemia on risk for neurodevelopmental disorders; for example, 
whether or not there is a dose response relationship between maternal glucose levels and risk for disorder.
Lack of reporting on GDM diagnostic criteria within the included studies is one of the reasons why over 
half of the studies were assessed as at high risk of bias, although removal of studies at high risk of bias in the 
ASD meta-analysis of ORs resulted in minimal change to the effect estimate. However, there was also substan-
tial diagnostic heterogeneity in the outcome of neurodevelopmental disorders, particularly in ADHD, where 
a broad range of questionnaires measuring levels of symptoms of ADHD were measured, which may not have 
met diagnostic threshold. Insufficient numbers of studies were available for ADHD to explore the impact that 
this may have had within a sensitivity analysis. A further limitation of the studies included within this review 
Author and year Study design Country
Sample size and 
age of children at 
diagnosis
Ascertainment of 
GDM diagnosis ADHD measure
Findings
[%, mean (SD), 
OR/HR/RR, β 
(95% CI)]
Risk of bias score 
(low–high: 0–2) Risk of bias
Xiang et al.  201836 Retrospective cohort USA
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Table 2.  Summary of studies measuring ADHD %: percentage, SD standard deviation, OR odds ratio, HR 
hazard ratio, RR risk ratio, β β coefficient, CI confidence interval. *Data provided by study author
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is that only some investigated the influence of other factors on the GDM and neurodevelopmental disorders 
association. This is discussed further below.
Potential mechanisms. The differences in risk between ASD and ADHD found in this review could be 
due to differing causal pathways, although clearly there are limitations to inferring any causality from observa-
tional studies. It could also be due to differences in the exposure, specifically degree of hyperglycaemia, although 
as previously discussed, this is often difficult to assess as so few studies consider it. Another possibility is that 
smaller sample sizes in the ADHD studies have failed to provide sufficient power to detect a difference in risk.
There were a few studies which looked at possible indicators of severity of GDM and degree of hyperglycae-
mia. For example, studies comparing GDM treated with medication versus without suggested an increased risk 
in medication-treated groups for both  ASD35 and  ADHD36. The pathway through which hyperglycaemia may 
impact neurodevelopment may be mediated by oxidative stress, which has been associated with adverse neu-
robehavioural outcomes such as motor  deficits13. It may also influence epigenetic changes in the offspring, such 
as reduced DNA methylation seen in neurodevelopmental disorders such as  ASD14. Moreover, hyperglycaemia 
can lead to systemic inflammation and pro-inflammatory cytokines are able to cross the placenta and the foetal 
blood–brain barrier, which may affect  neurodevelopment37. However, there may be critical periods of exposure to 
hyperglycaemia during pregnancy for the different neurodevelopmental conditions. Xiang et al. have conducted 
analyses in a large population-based cohort on risk for both  ASD38 and  ADHD36 following exposure to maternal 
diabetes. They found that the later the GDM is diagnosed, the lesser the risk of ASD but saw no association with 
ADHD which may indicate differing critical periods.
Women with GDM are at a greater risk of several adverse obstetric outcomes, such as pre-eclampsia, foetal 
macrosomia, perinatal mortality, Caesarean delivery and preterm  delivery9,39, which may also increase the risk of 
neurodevelopmental  disorders40. While some studies presented data on gestational age at birth and birthweight, 
none explored their role as a potential mediator. A number of studies also investigated the role of obesity and 
socioeconomic status (SES) as effect modifiers of the association between GDM and neurodevelopmental disor-
ders. Higher body mass index (BMI) increased the risk of both  ASD29,41 and  ADHD29,42,43 following exposure to 
GDM. Likewise, low SES has been shown to further increase the risk of  ADHD44,45 following exposure to GDM, 
although this has been less explored in ASD.
Implications and conclusions. Therefore, future potential areas for research include an investigation of 
these mechanistic pathways underlying the association between maternal hyperglycaemia across the spectrum 
of subclinical, gestational and pregestational diabetes, and adverse neurobehavioural outcomes. Baseline risk for 
neurodevelopmental disorders in the general population is relatively low so absolute risk for a neurodevelop-
mental disorder in the offspring of mothers with GDM is still relatively low and there are many children exposed 
to GDM during pregnancy who do not develop a neurodevelopmental disorder. This supports an approach to 
measuring risk on a continuum and is one of the reasons that we chose to include symptoms of disorder in addi-
tion to clinical diagnoses.
Figure 4.  Forest plot showing pooled unadjusted odds ratios for ADHD in those exposed to GDM versus those 
not exposed to GDM.
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A greater understanding of the early determinants of a child’s cognitive, social and emotional wellbeing would 
add support to interventions aimed at better management of these adversities, such as GDM, during pregnancy. 
Access to information about their condition has been identified as an enabler for women with GDM to manage 
their  condition46. Such information could include sensitively informing women about potential risks to their 
baby. There is now evidence that effective management results in reductions in obstetric morbidities such as 
shoulder dystocia and pre-eclampsia47. However, there is also some evidence to support an inverse correlation 
between level of hyperglycaemia in pregnancy and longer-term neurobehavioral outcomes in offspring, such 
as verbal  IQ48.
Furthering knowledge of these early predictors of adverse neurobehavioural outcomes would also under-
score the importance of interventions aimed at prevention of such adverse pregnancy exposures by targeting 
their broader determinants in early pregnancy or even earlier in the preconception period. For example, there 
is some evidence that diet and physical activity interventions in early pregnancy reduce gestational weight gain 
and may be associated with a reduced risk of  GDM49. That a number of studies included in the review found that 
socioeconomic status was an effect modifier of the association between GDM and neurodevelopmental disorders 
also highlights the importance of considering the broader determinants of health within healthcare. Thus there 
are a number of points at which healthcare professionals and policy makers involved in the care of women and 
children affected by GDM may usefully intervene.
In conclusion, there may be an association between GDM and the neurodevelopmental disorders of ASD 
and ADHD, with potentially differing levels of risk and mechanistic pathways for different neurodevelopmental 
disorders. Greater understanding of these risks and mechanisms may help to modify potential adverse develop-
mental trajectories from becoming established in children.
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